VA Committee
Cancers | Free Full-Text | 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Multiple Myeloma Treatment Options | First Line Therapy
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
SWOG - S2209- VRD-Lite Vs DRd-R Vs DRd-DR - Multiple Myeloma Clinical Trials
Multiple Myeloma Treatment Options | First Line Therapy
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Frontline Therapy in Multiple Myeloma
The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple My
Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis | SpringerLink
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Mohamad Mohty on Twitter: "VRD lite is a key player in my opinion @Mohty_EBMT #ASH17 https://t.co/eHqUTtQwMU" / Twitter
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
VRd Lite 療法
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients | Future Oncology
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Multiple Myeloma Tumor Board: Maintenance, Consolidation, and Continuous Therapy (Transcript)
Designing a Therapy Sequence for the Treatment of Multiple Myeloma
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Current approaches to management of newly diagnosed multiple myeloma - Goel - 2022 - American Journal of Hematology - Wiley Online Library
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
